Refocus Group, Inc.
Not enough financial coverage to compute a composite score for RFCS. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.refocus-group.com
Refocus Group, Inc. , a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia. The company develops VisAbility Micro-Insert System, an investigational medical device that is in clinical trials for use in the binocular presbyopic treatment.
- CEO
- J. Michael Judy
- IPO
- 2003
- Employees
- 4
- HQ
- Dallas, TX, US
Price Chart
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.58
- Avg Volume
- 47.40K
Get TickerSpark's AI analysis on RFCS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RFCS Coverage
We haven't published any research on RFCS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RFCS Report →